Colistimethate for Injection, USP is a sterile parenteral antibiotic product which, when reconstituted (see
) is suitable for intramuscular or intravenous administration. The color of the reconstituted solution is colorless to light yellow.
Each vial contains colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity) as a white to slightly yellow lyophilized cake. The sodium content is approximately 0.07 mg (0.003 mEq) of sodium per milligram of Colistin.
Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of
. This antibiotic is not indicated for infections due to
. Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms:
Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae
Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Media Articles Related to Colistimethate
ICU admission for older, low-risk patients with pneumonia associated with improved survival, with little difference in costs
Source: Medicare / Medicaid / SCHIP News From Medical News Today [2015.09.23]
Among Medicare beneficiaries hospitalized with pneumonia, intensive care unit (ICU) admission of patients which appeared to be discretionary was associated with improved survival and no significant...
Source: MedicineNet Creutzfeldt-Jakob Disease Specialty [2015.05.04]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 5/4/2015 12:00:00 AM
New research offers the potential of new treatments for Toxoplasma-induced pneumonia and cystic fibrosis
Source: Cystic Fibrosis News From Medical News Today [2015.05.01]
The research has discovered a link between a vital pumping system that does not function correctly in people with cystic fibrosis and the parasite Toxoplasma.
Alcohol abuse increases the risk of suffering from pneumonia
Source: Doctors Lounge - Chest Diseases
A decrease of the activity of the immune system in alcoholics may be responsible for an increased risk of pneumonia.
Flu vaccine reduces hospitalizations and deaths among nursing home residents
Source: Caregivers / Homecare News From Medical News Today [2015.09.09]
When the influenza vaccine is well matched to the prevailing strains of flu in a given season, patients in nursing homes are significantly less likely to be hospitalized or to die of pneumonia and...
Published Studies Related to Colistimethate
Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. [2010.12]
BACKGROUND: Cases of ventilator-associated pneumonia (VAP) due to multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa are common in hospitalized patients at Siriraj Hospital, Bangkok, Thailand. Parenteral colistimethate sodium (CMS) has been used for therapy of VAP caused by MDR A. baumannii and P. aeruginosa at Siriraj Hospital over the past few years, with modest favourable outcomes. Objectives To determine whether nebulized CMS as adjunctive therapy of Gram-negative VAP was safe and beneficial... CONCLUSIONS: Nebulized CMS as adjunctive therapy of Gram-negative VAP seems to be safe. However, a beneficial effect on clinical outcomes of adjunctive nebulized CMS for therapy of Gram-negative VAP was not ascertained.
Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. [2010.09.28]
Background Cases of ventilator-associated pneumonia (VAP) due to multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa are common in hospitalized patients at Siriraj Hospital, Bangkok, Thailand... However, a beneficial effect on clinical outcomes of adjunctive nebulized CMS for therapy of Gram-negative VAP was not ascertained.
Page last updated: 2015-09-23